A New Hampshire-based startup is changing how surgeons see inside the human body, and it just raised $33 million to prove it. See All AI, a medical technology company, has developed an artificial intelligence platform that turns standard 2D X-rays into detailed 3D images during surgery. This could eliminate the need for costly pre-op CT or MRI scans. The platform was recently demonstrated to both investors and surgeons, earning strong praise and accelerating its path toward clinical use. With global deployment in mind, the company aims to make advanced 3D imaging available to hospitals of all sizes and budgets.
How See All AI Transforms Fluoroscopy Into Instant 3D Surgical Views?
At the center of See All AI’s innovation is an AI-based platform that generates high-resolution 3D images from as few as two fluoroscopic X-rays. Fluoroscopy is a common, real-time X-ray method often used during surgery. What makes this platform remarkable is that it converts these images into 3D models with 1mm slice accuracy, in real time, without extra hardware.
That means no need for CT or MRI scans before surgery. No added radiation. No delays. Surgeons get the detail they need, right when they need it. According to CEO Eric Major, “We’re not selling expensive machines, we’re upgrading the ones hospitals already have.” The system is designed to work with the 150,000 existing fluoroscopy units worldwide, turning them into powerful 3D tools. It also uses a special visible light camera with onboard AI to track instruments with sub-millimeter accuracy.
See All AI’s Promising Tech Reduces Risk and Cost, Still Faces FDA Hurdles
In recent demonstrations using cadaveric models, the platform delivered CT-quality images on demand. The system also works without a direct line of sight, which allows surgeons to operate without changing their usual tools or techniques. This makes it especially valuable in minimally invasive surgery (MIS), where visibility is limited.
However, the technology is not yet FDA-cleared and isn’t available for clinical use. The company expects to submit for approval in 2025. Dr. Todd Albert, the Chief Medical Officer, said the impact could be “faster surgeries, lower radiation, and fewer complications.” Still, introducing new imaging tools into operating rooms is never simple. Hospitals will need to trust the AI, and regulators will want clear proof. The company believes their open, software-first approach will make adoption smoother and more affordable compared to older, hardware-heavy systems.
Will Smart Surgery Become the New Standard?
See All AI’s technology opens a big door, one that leads to less radiation, faster procedures, and cheaper equipment. But it also raises familiar questions: How much can surgeons rely on AI? Will smaller hospitals trust automated systems in critical procedures? And what role will regulation play?
Despite these unknowns, See All AI is moving fast. With three U.S. patent approvals underway and strong investor support, the company is poised to disrupt surgical imaging. Its vision is bold: real-time 3D navigation in every operating room, no matter the budget. If successful, this could redefine the meaning of “standard of care” in surgery and put next-generation tools in the hands of surgeons worldwide.
About The Author
